An announcement from Zevra Therapeutics ( (ZVRA)) is now available. Zevra Therapeutics has announced the commercial availability of MIPLYFFA™ (arimoclomol), the first FDA-approved treatment for ...

Shares of NASDAQ ZVRA opened at $8.11 on Wednesday. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The company has a market capitalization of $432.88 million, a price-to ...

Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the previous year, the business earned ($0.40) earnings per share.

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...

With the business potentially at an important milestone, we thought we'd take a closer look at Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) future prospects. Zevra Therapeutics, Inc. discovers and ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, ...

Zevra Therapeutics (NASDAQ:ZVRA) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market close.The consensus EPS Estimate is -$0.41 (-2.5% Y/Y) and the consensus ...

Zevra Therapeutics (ZVRA – Research Report) received a Buy rating and a price target from Cantor Fitzgerald analyst Kristen Kluska today. The company’s shares closed yesterday at $8.24.

CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment ...

CELEBRATION, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Neil F.